Infliximab
Brand: Remicade / Inflectra
Immunomodulator
TNF-alpha inhibitor (chimeric mAb)
Pharmacokinetics
| Half-life | 9.5 days |
| Clearance Route | reticuloendothelial |
| Active Metabolites | none |
| Notes | IV biologic. Weight-based dosing. Risk of infusion reactions and infections (TB, fungal). Check hepatitis B prior to treatment. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Infusion reactions, severe infections (TB, fungal), hepatotoxicity, reactivation of hepatitis B, demyelination, heart failure exacerbation
Contraindications:
Active infection, moderate–severe heart failure, untreated TB
Precautions:
Screen for TB & HBV; monitor LFTs; avoid live vaccines